From July @ to November @ , @ patients ( @ eligible ) were randomized to receive , every @ weeks , @ cycles of epirubicin @ mg/m@ followed by @ cycles of paclitaxel @ mg/m@ followed by @ cycles of intensified CMF ( Arm A ; @ patients ) , or @ cycles of epirubicin followed by @ cycles of CMF , as in Arm A , followed @ weeks later by @ weekly cycles of docetaxel @ mg/m@ ( Arm B ; @ ) , or @ weekly cycles of paclitaxel @ mg/m@ ( Arm C ; @ ) .